The pharmaceutical giant is backing RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19.It has made an undisclosed investment in VaxEquity, reported to be as much as ￡142million. The company is a spinout from Imperial College London set up last year, whose own RNA-based COVID-19 vaccine was an early contender during the pandemic. But it fell behind other mRNA rivals such as BioNTech and Moderna and so focused its efforts elsewhere. Imperial’s candidate

A panel of scientists advising Israel pointed to signs of waning immunity a few months after the third shot, and said that any delay in additional doses might prove too late to protect those most at risk.... It’s inevitable that we will see updated vaccine approaches.” Do you favour a Covid injection once a year to protect people from mutating strains?... Have your say in the comments section below. Stay up to date with the latest medical advancements and top tips for health care by signing up